Clinical Trial

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-06-16; most recent amendment 2025-10-23.
Status change: Not Yet Recruiting → Recruiting 2024-07-08
Trial Details
NCT Number NCT05919329
Lead Sponsor OHSU Knight Cancer Institute
Collaborators: Oregon Health and Science University, Progenics Pharmaceuticals, Inc.
Conditions Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
Enrollment 80 participants
Start Date 2024-06-25
Primary Completion 2028-09-01 (estimated)
Study Completion 2030-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-24